The patent buyout price for human papilloma virus (HPV) vaccine and the ratio of R&D costs to the patent value

Mario Songane, Volker Grossmann

Open source

DOI
10.1371/journal.pone.0244722
Published
2021-01-11
Container
PLOS ONE
Publisher
Public Library of Science (PLoS)
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1371/journal.pone.0244722,
  title = {The patent buyout price for human papilloma virus (HPV) vaccine and the ratio of R\&D costs to the patent value},
  author = {Mario Songane and Volker Grossmann},
  year = {2021},
  journal = {PLOS ONE},
  doi = {10.1371/journal.pone.0244722},
  url = {https://doi.org/10.1371/journal.pone.0244722}
}

RIS

TY  - JOUR
TI  - The patent buyout price for human papilloma virus (HPV) vaccine and the ratio of R&D costs to the patent value
AU  - Mario Songane
AU  - Volker Grossmann
PY  - 2021
JO  - PLOS ONE
DO  - 10.1371/journal.pone.0244722
UR  - https://doi.org/10.1371/journal.pone.0244722
ER  - 

APA

Songane, M., & Grossmann, V. (2021). The patent buyout price for human papilloma virus (HPV) vaccine and the ratio of R&D costs to the patent value. PLOS ONE. https://doi.org/10.1371/journal.pone.0244722

Source records